Patient and donor antibody profiles in early COVID-19 convalescent plasma therapy in the COnV-ert trial.

Front Immunol · 2025 · PMC12507808 · PMID 41080591

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Two trials [CCP-Argentina ( 12 ) and CSSC-004 ( 14 )] demonstrated a significant reduction in disease progression or hospitalization risk, two others [COnV-ert ( 10 ) and C3PO ( 11 )] found no clinical efficacy, and a fifth trial [COV-Early ( 13 )] suggested potential efficacy that did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.